Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPRG | P23470 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125688 | 0.97 | — | — | |
| SCHEMBL29405402 | 0.97 | — | — | |
| Ether SCHEMBL1973931 | 0.79 | SLC6A4 (0.43) | AHRTP53TSHRALDH1A1KMT2A | |
| Propionaldehyde SCHEMBL27753762 | 0.78 | ALDH1A1 (0.42) | TSHRCYP3A4ALDH1A1KMT2AHTR2A | |
| SCHEMBL29511324 | 0.77 | — | — | |
| SCHEMBL18361943 | 0.77 | S100A4 (0.46) | AHRALDH1A1CYP2A6PTPRCDHODH | |
| SCHEMBL4899529 | 0.77 | — | — | |
| SCHEMBL11318966 | 0.77 | — | — | |
| SCHEMBL3747323 | 0.76 | CYP3A4 (0.50) | CYP3A4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1508806 | 0.76 | LMNA (0.44) | TP53ALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| CN-111689995-A | High-solubility triaryl carbon borate and preparation method and application thereof | 万华化学集团股份有限公司 | 2020-09-22 | — | — | CN | disclosed |
| CN-104918938-B | The novel derovatives of three ring 3,4 dihydro 2H pyridos [1,2 a] pyrazine 1,6 as gamma secretase modulators | 詹森药业有限公司 | 2017-08-15 | — | — | CN | disclosed |
| EP-2684871-B1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | disclosed |
| CN-104918938-A | Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-[alpha]]pyrazine-1,6-dione derivatives as gamma secretase modulators | JANSSEN PHARMACEUTICA NV | 2015-09-16 | — | — | CN | disclosed |
| EP-2886548-A1 | METHOD FOR PRODUCING BORINIC ACID DERIVATIVE, AND NOVEL BORINIC ACID DERIVATIVE | Manac Inc. (JP) | 2015-06-24 | — | — | EP | disclosed |
| CN-103261176-B | 1, 4-oxazepane derivatives | TAKEDA PHARMACEUTICAL | 2015-06-03 | — | — | CN | disclosed |
| US-20150105562-A1 | METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES | MANAC INC. (JP) | 2015-04-16 | — | — | US | disclosed |
| CN-104395326-A | Process for producing borinic acid derivative and novel borinic acid derivative | MANAC INC | 2015-03-04 | — | — | CN | disclosed |
| CN-104024251-A | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC | 2014-09-03 | — | — | CN | disclosed |
| WO-2008074703-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| CN-1922148-A | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2007-02-28 | — | — | CN | disclosed |
| CN-1911930-A | Chemokine receptor anagonists, methods and use therefor | MILLENNIUM PHARM INC (US) | 2007-02-14 | — | — | CN | disclosed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | disclosed |
| WO-2005058881-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| CN-1585772-A | Chemokine receptor antagonists and methods and uses thereof | MILLENNIUM PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1423106-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003014097-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105562-A1 | METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES | ADORA2B, TPSAB1, ACVR2B | AHR 914/4885TP53 4479/4885TSHR 549/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | AHR 37/4885TP53 829/4885TSHR 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.